Combination immunotherapy before surgery for advanced ovarian cancer
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests a new combination of drugs given before surgery to shrink advanced ovarian cancer, which may make it easier to remove and improve outcomes. It includes an immunotherapy drug that helps your immune system fight cancer, along with standard chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a type of ovarian, fallopian tube, or peritoneal cancer called high-grade serous carcinoma.
- Your cancer is at an advanced stage (stage IIIC or IV) and doctors think it cannot be fully removed with surgery right away.
- You are generally able to care for yourself (ECOG score 0 or 1).
- You have not had any previous cancer treatment.
- You do not have an autoimmune disease or take drugs that suppress your immune system.
- You are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an immune-based treatment (IMNN-001/GEN-1) combined with standard chemotherapy given before and during surgery. It’s for people with newly diagnosed advanced high-grade serous ovarian, fallopian tube, or primary peritoneal cancer to see if it can improve outcomes.
This trial is testing a combination of two new immunotherapy drugs (iparomlimab and tuvonralimab) given before surgery and together with chemotherapy for advanced ovarian cancer. It aims to see if this approach can shrink the cancer more effectively and improve outcomes.
This trial tests a combination of two immunotherapy drugs, bevacizumab, and chemotherapy given before surgery for advanced ovarian cancer. The goal is to shrink tumors to make surgery more effective and potentially improve outcomes.
This trial tests a combination of two immunotherapy drugs with chemotherapy, with or without a targeted therapy pill, given before surgery for advanced ovarian cancer. It aims to shrink tumors to make surgery more effective and potentially improve outcomes.
This trial tests a new combination of treatments for advanced ovarian, fallopian tube, or peritoneal cancer. It combines chemotherapy and immunotherapy (drugs that help your immune system fight cancer) with a special vaccine made from your own tumor. The goal is to see if this approach is more effective than standard treatment.
This trial tests a combination of three targeted drugs (olaparib, durvalumab, and bevacizumab) as a first treatment for advanced ovarian cancer. It aims to shrink tumors before possible surgery, potentially improving outcomes.
Hear when a new Primary Peritoneal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.